Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.53 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.47 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.46 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144625 | 0.98 | PTPN22 (0.60) | PTPN22POLBALDH1A1KDM4EGAA | |
| SCHEMBL7991059 | 0.98 | PTPN22 (0.60) | PTPN22POLBALDH1A1KDM4EGAA | |
| SCHEMBL29578671 | 0.98 | PTPN22 (0.60) | PTPN22POLBALDH1A1KDM4EGAA | |
| Benzene SCHEMBL28007586 | 0.93 | PTPN22 (0.56) | PTPN22POLBALDH1A1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL7251476 | 0.93 | PTPN22 (0.56) | PTPN22POLBALDH1A1KDM4EGAA | |
| Sulfuric Acid SCHEMBL11773839 | 0.88 | ERN1 (0.52) | PTPN22POLBALDH1A1KDM4EGAA | |
| SCHEMBL8386315 | 0.87 | HPRT1 (0.58) | PTPN22POLBALDH1A1KDM4EGAA | |
| SCHEMBL9350116 | 0.83 | PTPN22 (0.54) | PTPN22POLBALDH1A1KDM4EGAA | |
| 3-Aminophenol SCHEMBL8003427 | 0.82 | ALDH1A1 (0.57) | PTPN22POLBALDH1A1KDM4EGAA | |
| SCHEMBL11750928 | 0.78 | ALDH1A1 (0.45) | PTPN22POLBALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224335-A1 | INK COMPOSITION AND METHOD OF FABRICATING LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | KIM SUNG-HEE | 2011-09-15 | — | — | US | claimed |
| US-7935552-B2 | Ink composition and method of fabricating liquid crystal display device using the same | LG DISPLAY CO., LTD. (KR) | 2011-05-03 | — | — | US | claimed |
| US-20100120181-A1 | INK COMPOSITION AND METHOD OF FABRICATING LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | LG DISPLAY CO., LTD. (KR) | 2010-05-13 | — | — | US | claimed |
| JP-6223819-A | — | — | None | — | — | JP | disclosed |
| EP-4577017-A1 | OPTICAL OUTCOUPLING MATERIAL, ORGANIC LIGHT EMITTING DEVICE, DISPLAY DEVICE, PROCESS FOR PREPARING THE ORGANIC LIGHT EMITTING DEVICE AND COMPOUND | Novaled GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| EP-4543863-A1 | FERROPTOSIS INHIBITORS AND USES THEREOF | University Of Ottawa (CA) | 2025-04-30 | — | — | EP | disclosed |
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-30 | — | — | US | disclosed |
| WO-2023245297-A1 | FERROPTOSIS INHIBITORS AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2023-12-28 | — | — | WO | disclosed |
| EP-4284372-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | University of Florida Research Foundation, Incorporated (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-4232161-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116323571-A | Covalent inhibitors of Creatine Kinase (CK) and their use for the treatment and prevention of cancer | 丹娜法伯癌症研究院 | 2023-06-23 | — | — | CN | disclosed |
| US-5801243-A | REACTING A SUBSTITUTED ALDEHYDE WITH A SUBSTITUTED ORTHO-AMINO-HYDROXY AROMATIC COMPOUND | OPTISCHE WERKE G. RODENSTOCK (DE) | 1998-09-01 | — | — | US | disclosed |
| US-5789412-A | 5-HYDROXYTRYPTAMINE (SEROTONIN) RECEPTOR ANTAGONISTS FOR THE CURATIVE OR PREVENTIVE TREATMENT OF PAIN, DEPRESSION, OBSESSIVE COMPULSIVE DISORDERS, ANXIETY OR PANIC ATTACK, OR CANCER | PIERRE FABRE MEDICAMENT (FR) | 1998-08-04 | — | — | US | disclosed |
| EP-0783483-A1 | METHOD FOR PREPARING PHOTOCHROMIC COMPOUNDS OF THE SPIRO INDOLIN- 2,3']-BENZOXAZINE] RINGED TYPE | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996003368-A1 | METHOD FOR PREPARING PHOTOCHROMIC COMPOUNDS OF THE SPIRO[INDOLIN-[2,3']-BENZOXAZINE] RINGED TYPE | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 1996-02-08 | — | — | WO | disclosed |
| EP-0656893-A1 | PHOTOCHROMIC OXAZINE COMPOUNDS | Optische Werke G. Rodenstock (DE) | 1995-06-14 | — | — | EP | disclosed |
| WO-1995000500-A1 | PHOTOCHROMIC OXAZINE COMPOUNDS | OPTISCHE WERKE G. RODENSTOCK (DE) | 1995-01-05 | — | — | WO | disclosed |
| JP-H06223819-A | NON-AQUEOUS ELECTROLYTE BATTERY | RES DEV CORP OF JAPAN | 1994-08-12 | — | — | JP | disclosed |
| US-4429133-A | OPTICAL BRIGHTENERS FOR POLYACRYLONITRILE | SANDOZ LTD. (CH) | 1984-01-31 | — | — | US | disclosed |
| US-4054456-A | Diazo photographic materials containing 2-hydroxy 3-naphthanilide coupler | FUJI PHOTO FILM CO., LTD. (JA) | 1977-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | NLN, OAT, PC | GAA 72/4885GLA 92/4885HDAC3 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.